NASDAQ: NAMSNewamsterdam Pharma Co Nv Stock Ownership - Who owns Newamsterdam Pharma Co Nv?
Insider buying vs selling
Have Newamsterdam Pharma Co Nv insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Louise Frederika Kooij | Chief Accounting Officer | 2024-10-01 | 45,000 | $15.72 | $707.40kSell |
| Juliette Berangere Audet | Chief Business Officer | 2024-09-26 | 1,104 | $15.70 | $17.33kBuy |
| Michael H. Davidson | Chief Executive Officer | 2024-08-20 | 5,000 | $16.27 | $81.35kBuy |
| Michael H. Davidson | Chief Executive Officer | 2024-06-20 | 5,000 | $17.26 | $86.31kBuy |
| James N. Topper | Director | 2024-03-26 | 8,429 | $21.50 | $181.22kBuy |
| Johannes Jacob Pieter Kastelein | Chief Scientific Officer | 2024-03-26 | 190,476 | $21.50 | $4.10MSell |
| Johannes Jacob Pieter Kastelein | Chief Scientific Officer | 2024-03-26 | 11,197 | $22.72 | $254.40kSell |
| Louis G. Lange | Director | 2024-02-13 | 5,000 | $19.00 | $95.00kBuy |
NAMS insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when NAMS insiders and whales buy or sell their stock.
NAMS Shareholders
What type of owners hold Newamsterdam Pharma Co Nv stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| James N. Topper | 16.23% | 14,610,429 | $265.76M | Insider |
| Frazier Life Sciences Management LP | 13.58% | 12,226,943 | $222.41M | Institution |
| Nap Bv Forgrowth | 13.14% | 11,831,461 | $215.21M | Insider |
| Fcpm Iii Services Bv | 13.14% | 11,831,461 | $215.21M | Institution |
| Bain Capital Life Sciences Investors LLC | 11.64% | 10,473,913 | $190.52M | Insider |
| Bain Capital Life Sciences Investors LLC | 11.64% | 10,473,913 | $190.52M | Institution |
| Ra Capital Management LP | 8.96% | 8,064,000 | $146.68M | Institution |
| Viking Global Investors LP | 8.91% | 8,024,565 | $145.97M | Institution |
| Medicxi Ventures Management Jersey Ltd | 3.19% | 2,869,565 | $52.20M | Institution |
| James E. Flynn | 2.76% | 2,480,199 | $45.11M | Insider |
NAMS vs Biotech Stocks
Newamsterdam Pharma Co Nv Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.